首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1842724

DNA癌症疫苗的全球市場:臨床試驗，開發技術平台，市場機會預測(2026年)

Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球DNA癌症疫苗市場：臨床試驗、技術平台開發及市場機會展望（2026）報告的主要發現與亮點

首個DNA癌症疫苗預計將於2030年獲得商業批准
正在進行臨床試驗的DNA癌症疫苗：超過20種疫苗
全球DNA癌症疫苗臨床試驗洞察：按公司、適應症和階段劃分
DNA癌症疫苗開發技術平台洞察：超過10個平台
與其他癌症免疫療法的比較
DNA癌症疫苗的最新創新
競爭格局

癌症DNA疫苗的需求及本報告的意義

癌症持續存在…癌症在全球範圍內造成了毀滅性的影響，新增病例數百萬，死亡率居高不下，尤其對於晚期和難治性癌症而言更是如此。雖然免疫療法（例如免疫檢查點抑制劑）徹底改變了癌症治療格局，但它們並非完全有效。 DNA疫苗透過遞送編碼在質粒DNA中的腫瘤特異性抗原，活化人體的免疫反應來識別和靶向癌細胞，標誌著癌症治療進入了一個新時代。 DNA疫苗因其安全性、穩定性、快速生產和個人化/可調控性而備受青睞。

這份及時且亟需的報告為從研究人員到投資者的利害關係人提供了關於當前癌症DNA疫苗研發狀況的清晰見解。它總結了現有的臨床活動、新興技術、關鍵公司和策略合作夥伴關係。隨著該領域的快速發展，這份報告以清晰易懂的方式呈現了創新的發展方向、重要性以及它將如何改變癌症治療的未來。

本報告涵蓋的癌症DNA疫苗臨床試驗概況

DNA疫苗目前正處於臨床開發階段，許多疫苗已進入中後期開發階段。其中，Inovio Pharmaceuticals公司針對HPV相關子宮頸癌的候選疫苗是目前最先進的候選疫苗之一，該疫苗採用電穿孔技術遞送質粒DNA，展示了DNA疫苗如何用於抗病毒驅動的癌症。 Imunon公司的IMNN-001目前正在進行卵巢癌的臨床試驗，該疫苗將DNA與IL-12免疫刺激療法和化療相結合，並在II期臨床試驗中顯示出令人鼓舞的生存趨勢。

本概述重點介紹了黑色素瘤、肺癌和前列腺癌的全球臨床試驗，深入分析了臨床試驗階段、遞送策略、聯合用藥方案和免疫學終點。所提供的數據有助於了解哪些策略最接近臨床應用，以及未來的研究方向。

技術平台、合作關係與協定

平台和遞送技術的進步是DNA疫苗技術的基石。雖然電穿孔仍然是提高疫苗吸收率的主要方法，但其他系統正在迅速發展。例如，NEC生物治療公司正在測試一種口服DNA疫苗，該疫苗利用機器學習來識別和針對患者特異性的腫瘤突變。 Imunon公司的PlaCCine®平台最初是為傳染病設計的，但由於其能夠以更高的穩定性遞送多種抗原，因此正在被重新用於腫瘤治療。

本報告概述了重要的合作項目，包括Immunocure與PharmaJet的合作，後者採用無針皮內注射系統來提高患者依從性和免疫反應。這些合作是將專有DNA構建體與第三方遞送系統結合以加快開發和規模化生產的更大趨勢的一部分。

癌症DNA疫苗研發領域的主要公司

許多公司處於該領域的前沿。 Inovio、Scancell、Imunon和NEC Bio都在研發和臨床試驗方面投入了大量資源。 Scancell的皮內注射iSCIB1+黑色素瘤疫苗與免疫檢查點抑制劑合併使用，目前正在透過英國國家醫療服務體系（NHS）癌症疫苗啟動平台招募病患。本報告對這些公司及其他公司進行了介紹，概述了它們的研發管線、感興趣的治療領域、遞送機制和策略合作夥伴關係。

報告展望癌症DNA疫苗的未來發展方向

本報告指出，癌症DNA疫苗領域存在著推動下一代創新發展的巨大機遇，包括應用微環DNA（mcDNA）實現更清潔、更高效的基因表達；開發基於DNA摺紙技術的平台（如DoriVac）進行靶向免疫刺激；以及利用基因編輯工具（包括CRISPR）優化疫苗構建體。

此外，諸如 LungVax（一種目前正在英國研發的針對肺癌高危險群的 DNA 疫苗）等預防性方法表明，DNA 疫苗的應用範圍將超越治療範疇。

隨著臨床證據的累積、遞送裝置的改進以及與現有療法相容性的提高，DNA 癌症疫苗有望在未來幾年成為癌症治療的核心支柱。

First DNA Cancer Vaccine commercial Approval Expected By 2030
DNA Cancer Vaccines In Clinical Trials: > 20 Vaccines
Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase
Insight On DNA Cancer Vaccine Development Technology Platforms: >10 Platforms
Comparison With Other Cancer Immunotherapies
DNA Cancer Vaccines Recent Innovations
Competitive Landscape

Need For Cancer DNA Vaccines and Why This Report

The global impact of cancer remains profound, with millions of new cases and high mortality, particularly in advanced and hard to treat cancers. Although immunotherapies such as checkpoint inhibitors have transformed the cancer therapeutic landscape, they are not effective across the board. DNA vaccines present a new era of cancer therapy by providing tumor specific antigens encoded in plasmid DNA that activate the body's immune response to detect and target cancer cells. They are attractive due to their safety, stability, fast production, and the ability to be tailored or personalized.

This report is timely and much needed, providing stakeholders, ranging from researchers to investors, clear insight into the current state of cancer DNA vaccine development. It summarizes the existing clinical activity, nascent technologies, key companies, and strategic partnerships. As the field rapidly advances, the report delivers a well-curated, recent snapshot of where innovation is headed, why it is important, and how it might transform the future of cancer care.

Cancer DNA Vaccines Clinical Trials Insight Covered In Report

DNA vaccines are currently in clinical development, many of them moving into mid to late stage testing. One of the most advanced, Inovio Pharmaceuticals' HPV-associated cervical cancer candidate based on plasmid DNA administered using electroporation, shows how DNA vaccines can be used against virus-driven cancers. IMUNON's IMNN-001, being tested for ovarian cancer, combines DNA with IL-12 immunostimulation and chemotherapy and is reporting promising survival trends in Phase II.

This overview calls attention to the scale of global clinical trials, such as melanoma, lung, and prostate cancer, and offers insights into trial phases, delivery strategies, combination regimens, and immunological endpoints. Data provided serves to place into context which strategies are most proximal to clinical translation and how future efforts will look like.

Technology Platforms, Partnerships & Agreements

Platform and delivery advancements are the cornerstone of DNA vaccine technology. Electroporation is still a dominant way to deliver improved uptake, but other systems are picking up steam. NEC Bio Therapeutics, for example, is testing an oral, bacteria-delivery based DNA vaccine that uses machine learning to identify patient-specific tumor mutations for targeting. IMUNON's PlaCCine(R) platform, initially designed for infectious disease, is being repurposed for oncology because it has the ability to deliver multiple antigens with improved stability.

The report outlines major collaborations, including Immuno Cure and PharmaJet's partnership, which employs a needle-free intradermal injection system to enhance patient compliance and immune response. These collaborations are part of a larger trend of merging proprietary DNA constructs with third-party delivery systems for faster development and scale-up.

Leading Companies Active In RandD On Cancer DNA Vaccines

A number of companies are at the forefront in this field. Inovio, Scancell, IMUNON, and NEC Bio are all committing significant resources to R&D and clinical trials. Scancell's intradermally delivered iSCIB1+ melanoma vaccine, administered in combination with checkpoint inhibitors, is recruiting patients on the UK's NHS Cancer Vaccine Launch Pad. The report outlines these companies and others, providing an overview of their pipelines, therapeutic areas of interest, delivery mechanisms, and strategic partnerships.

Report Indicating Future Development Of Cancer DNA Vaccines

Looking ahead, the report points out significant opportunities fueling the next generation of innovation. These are the application of minicircle DNA (mcDNA) for cleaner, more efficient gene expression, the development of DNA origami-based platforms such as DoriVac for targeted immune stimulation, and gene editing tools including CRISPR to optimize vaccine constructs. Furthermore, preventive approaches such as LungVax, a DNA vaccine in development in the UK for patients at high risk of lung cancer, point to an even wider use of DNA vaccines beyond therapy.

As more clinical evidence mounts, improved delivery devices, and compatibility with current therapies, DNA cancer vaccines will be a central column of oncology treatment in the years to come.

1. Overview Of DNA Cancer Vaccines

1.1 What Are DNA Cancer Vaccines?
1.2 History & Development Timeline
1.3 Comparison With Other Cancer Immunotherapies
1.4 Advantages & Limitations

2. DNA Cancer Vaccines - Mechanism of Action

2.1 How DNA Vaccines Work
2.2 Antigen Selection & Delivery
2.3 Role Of Vectors & Adjuvants
2.4 Immune Activation Pathways

3. Global DNA Cancer Vaccines - Recent Innovations

4. Global DNA Cancer Vaccines Market Overview

4.1 Current Market Scenario
4.2 Future Opportunity Outlook

5. DNA Cancer Vaccine Development Trends By Indication

5.1 Prostate Cancer
5.2 Cervical Cancer
5.3 Lung Cancer
5.4 Melanoma
5.5 Breast Cancer

6. DNA Cancer Vaccine Development Technology Platforms

7. Global DNA Cancer Vaccines Clinical Trials Overview

7.1 By Company
7.2 By Indication
7.3 By Phase

8. Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II
8.5 Phase III

9. Global DNA Cancer Vaccines Market Dynamics

9.1 Growth Drivers & Opportunities
9.2 Market Restraints & Solutions

10. Competitive Landscape

10.1 4basebio
10.2 Aston Sci
10.3 Genexine
10.4 Evaxion
10.5 Immunomic Therapeutics
10.6 INOVIO
10.7 Madison Vaccines
10.8 Nykode Therapeutics
10.9 PapiVax Biotech
10.10 Takis

簡介目錄圖表

List of Figures

Figure 1-1: DNA Cancer Vaccines - Mechanism
Figure 1-2: DNA Cancer Vaccine - Milestones
Figure 1-3: DNA Cancer Vaccines - Safety Profile
Figure 1-4: DNA Vaccines vs. Other Immunotherapies - Durability Of Response
Figure 1-5: DNA Vaccine Delivery Methods
Figure 1-6: DNA Vaccine Immunogenicity - Challenges
Figure 2-1: DNA Vaccine Immune Response
Figure 2-2: DNA Vaccine - Antigen Presentation To Immune System
Figure 2-3: DNA Cancer Vaccine - Final Immune Response
Figure 2-4: Types Of Tumor Antigens
Figure 2-5: Challenges with Antigen Selection
Figure 2-6: Plasmid Vectors
Figure 2-7: Bacterial Vectors
Figure 2-8: Viral Vectors
Figure 2-9: Adjuvants In DNA Cancer Vaccines
Figure 2-10: New Developments In Adjuvants
Figure 2-11: DNA Sensors & Their Roles in Immune Activation
Figure 3-1: DoriVac DNA Vaccine Mechanism
Figure 3-2: μEPO System - Key Features & Breakthroughs
Figure 3-3: Neomatrix Biotech: Revolutionizing Personalized Cancer Immunotherapy
Figure 4-1: Global DNA Cancer Vaccines Market - Future Opportunities
Figure 5-1: UW18037 Phase 2 (NCT04090528) Study - Initiation & Completion Year
Figure 5-2: UW25025 Phase 1 (NCT07090148) Study - Initiation & Completion Year
Figure 5-3: UW18008 Phase 2 (NCT03600350) Study - Initiation & Completion Year
Figure 5-4: J23105sIRB Phase 1 (NCT06315257) Study - Initiation & Completion Year
Figure 5-5: J1955 Phase 2 (NCT04131413) Study - Initiation & Completion Year
Figure 5-6: BB IND 18340 Phase 1 (NCT03913117) Study - Initiation & Completion Year
Figure 5-7: NEWISH-HPV-101 Phase 1 (NCT06276101) Study - Initiation & Completion Year
Figure 5-8: 202104143 Phase 2 (NCT04397003) Study - Initiation & Completion Year
Figure 5-9: NCI-2021-14159 Phase 2 (NCT05242965) Study - Initiation & Completion Year
Figure 5-10: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-11: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-12: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-13: W81XWH-15-1-0101 Phase 1 (NCT02204098) Study - Initiation & Completion Year
Figure 5-14: NCI-2014-01070 Phase 1 (NCT02157051) Study - Initiation & Completion Year
Figure 5-15: NCI-2025-04692 Phase 2 (NCT07112053) Study - Initiation & Completion Year
Figure 5-16: NCI-2020-01662 Phase 2 (NCT04329065) Study - Initiation & Completion Year
Figure 5-17: NECVAX-NEO1-05-DE Phase 1/2 (NCT06631092) Study - Initiation & Completion Year
Figure 6-1: Enzymatic manufacturing process
Figure 6-2: Genexine - DNA Vaccine Platform
Figure 6-3: MVI Technology - DNA Plasmid Mechanism Of Action
Figure 6-4: Nykode - Protein Format
Figure 6-5: Nykode Therapeutics - DNA Vaccine Mechanism Of Action
Figure 6-6: DNA Medicines Technology - INOVIO
Figure 6-7: UNITE - Mode Of Action
Figure 6-8: GT-EPIC Platform - Process
Figure 6-9: LineaDNA - Production Process
Figure 6-10: GeneOne DNA Plasmid Technology - Principle
Figure 6-11: Fusogenix - FAST Protein Structure
Figure 6-12: PLV Technology
Figure 6-13: PLV Technology - Delivery Mechanism
Figure 7-1: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Company , 2025 -2026
Figure 7-2: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2025 -2026
Figure 7-3: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2025 - 2026
Figure 9-1: Global DNA Cancer Vaccines Market - Drivers & Opportunities
Figure 9-2: Global DNA Cancer Vaccines Market - Restraints & Solutions